IGF1 and adenoma: I consider second-generation SSAs as the first-line treatment post-surgery for any symptomatic patient with above normal IGF-1(≥1.5–2 ULN) and unresectable residual tumors, particularly in cases of hyperintense lesions on T2 on MRI or adenomas with sparsely granulated pathology.